8-chloro-3-methyl-N2-(4-(trifluoromethyl)pyridin-2-yl)quinoline-2,5-diamine | 1381954-37-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 8-chloro-3-methyl-N2-(4-(trifluoromethyl)pyridin-2-yl)quinoline-2,5-diamine
• 英文别名: 8-chloro-3-methyl-2-N-[4-(trifluoromethyl)pyridin-2-yl]quinoline-2,5-diamine
• CAS: 1381954-37-5
• 化学式: C₁₆H₁₂ClF₃N₄
• 分子量: 352.746
• InChiKey: LMKDXRLMPNWFJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Compounds useful for treating AIDS
  申请人：Société Splicos

  公开号：EP2465502A1

  公开（公告）日：2012-06-20

  The present invention relates to compound (I) for use as an agent for preventing, inhibiting or treating AIDS. The present invention further relates to compounds of formula (I) wherein X is CR0 or N; R0, R1, R2, R3, R4, R7 and R8 independently represent a hydrogen atom, a halogen atom or a group chosen among a (C1-C5)alkyl group, a (C3-C6)cycloalkyl group, a (C1-C5)fluoroalkyl group, a (C1-C5)alkoxy group, a (C1-C5)fluoroalkoxy group, a -CN group, a -COORa group, a -NO2 group, a -NRaRb group, a -NRa-SO2-NRaRb group, a -NRa-SO2-Ra group, a -NRa-C(=O)-Ra group, a -NRa-C(=O)-NRaRb group, a -SO2-NRaRb group, a -SO3H group, a -OH group, a -O-SO2-ORc group, a -O-P(=O)-(ORc)(ORd) group, a -O-CH2-COORc group and can further be a group chosen among: R5 represents a hydrogen atom, a (C1-C5)alkyl group or a (C3-C6)cycloalkyl group; R10 is a hydrogen atom or a chlorine atom, and R11 is a hydrogen atom or a (C1-C4)alkyl group or anyone of its pharmaceutically acceptable salts.

  本发明涉及用于防止、抑制或治疗艾滋病的化合物（I）。本发明进一步涉及公式（I）的化合物，其中X是CR0或N；R0、R1、R2、R3、R4、R7和R8独立地代表一个氢原子、一个卤素原子或一个选自（C1-C5）烷基团、（C3-C6）环烷基团、（C1-C5）氟烷基团、（C1-C5）烷氧基团、（C1-C5）氟烷氧基团、-CN基团、-COORa基团、-NO2基团、-NRaRb基团、-NRa-SO2-NRaRb基团、-NRa-SO2-Ra基团、-NRa-C(=O)-Ra基团、-NRa-C(=O)-NRaRb基团、-SO2-NRaRb基团、-SO3H基团、-OH基团、-O-SO2-ORc基团、-O-P(=O)-(ORc)(ORd)基团、-O-CH2-COORc基团，并且还可以是一个选自：R5代表一个氢原子、一个（C1-C5）烷基团或一个（C3-C6）环烷基团；R10是一个氢原子或一个氯原子，R11是一个氢原子或一个（C1-C4）烷基团或其药用可接受盐的任何一个。
• Quinoline derivatives for use in the treatment or prevention of viral infection
  申请人：ABIVAX

  公开号：EP3058940A1

  公开（公告）日：2016-08-24

  The present invention relates to A quinoline derivative of formula (I) or anyone of its pharmaceutically acceptable salt, or anyone of its metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient; and then terminating said treatment when: the viral load is low or undetectable; and/or the level of CD4+ cell count is maintained or restored. The present invention further relates to a quinoline derivative of formula (I) as defined in claim 1, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, for which an ineffectiveness or a decline in a prior anti-retroviral treatment effectiveness has been stated and to a quinoline derivative of formula (I) as defined above, or anyone of its pharmaceutically acceptable salts and metabolites, for use for treating or preventing a viral infection, in particular a HIV infection or a HIV-related condition in a patient, wherein the patient is infected by a drug-resistant viral strain, and more particularly by a drug-resistant HIV strain.

  本发明涉及一种式 (I) 的喹啉衍生物 或其任何一种药学上可接受的盐，或其任何一种代谢物、 用于治疗或预防患者的病毒感染，特别是 HIV 感染或 HIV 相关疾病；当病毒载量低或检测不到；和/或 CD4+ 细胞计数水平保持或恢复时，终止上述治疗。 本发明进一步涉及权利要求 1 所定义的式 (I) 喹啉衍生物或其任何一种药学上可接受的盐和代谢物，用于治疗或预防病毒感染，特别是艾滋病病毒感染或患者的艾滋病病毒相关病症，之前的抗逆转录病毒治疗效果无效或下降，本发明还涉及如上定义的式 (I) 喹啉衍生物、或其任何一种药学上可接受的盐和代谢物，用于治疗或预防病毒感染，特别是患者的 HIV 感染或 HIV 相关病症，其中患者感染的是耐药病毒株，尤其是耐药 HIV 株。
• QUINOLINE DERIVATIVES FOR USE INE THE TRAEATMENT OF INFLAMMATION DISEASES
  申请人：ABIVAX

  公开号：EP3669873A1

  公开（公告）日：2020-06-24

  The present disclosure relates to quinoline derivatives of Formula (I): wherein each R is independently hydrogen, halogen, -CN, hydroxyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, (C3-C6)cycloalkyl, -NO2, -NR1R2, (C1-C4)alkoxy, phenoxy, -NR1-SO2-NR1R2, -NR1-SO2-R1, -NR1-C(=O)-R1, -NR1-C(=O)-NR1R2,-SO2-NR1R2, -SO3H, -O-SO2-OR3, -O-P(=O)-(OR3)(OR4), -O-CH2-COOR3, (C1-C3)alkyl, said alkyl being optionally mono- or di-substituted by a hydroxyl group; each R' is independently hydrogen, (C1-C3)alkyl, hydroxyl, halogen, -NO2, -NR1R2, morpholinyl, morpholino, N-methylpiperazinyl, (C1-C3)fluoroalkyl, (C1-C4)alkoxy, -O-P(=O)-(OR3)(OR4), -CN, or other groups; for use for preventing and/or treating inflammatory disease, disorder, or conditions.

  本公开涉及式 (I) 的喹啉衍生物： 其中每个 R 独立地为氢、卤素、-CN、羟基、(C1-C3)氟烷基、(C1-C3)氟烷氧基、(C3-C6)环烷基、-NO2、-NR1R2、(C1-C4)烷氧基、苯氧基、-NR1-SO2-NR1R2、-NR1-SO2-R1、-NR1-C(＝O)-R1、-NR1-C(＝O)-NR1R2、-SO2-NR1R2、-SO3H、-O-SO2-OR3、-O-P(＝O)-(OR3)(OR4)、-O-CH2-COOR3、(C1-C3)烷基，所述烷基可任选被羟基单取代或二取代；每个 R'独立地为氢、(C1-C3)烷基、羟基、卤素、- 、-NR1R2、吗啉基、吗啉基、N-甲基哌嗪基、(C1-C3)氟烷基、(C1-C4)烷氧基、-O-P(=O)-(OR3)(OR4)、-CN 或其他基团；用于预防和/或治疗炎症性疾病、紊乱或病症。
• QUINOLINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF CANCER
  申请人：ABIVAX

  公开号：EP3669874A1

  公开（公告）日：2020-06-24

  A quinoline derivative of formula (I') wherein R independently represent a halogen atom or a group chosen among a (C1-C3)fluoroalkyl group, a (C1-C3)fluoroalkoxy group, a -NR1R2 group, a (C1-C4)alkoxy group and a (C1-C3)alkyl group, said alkyl being optionally mono or di-substituted by a hydroxyl group, R' independently represent a halogen atom or a group chosen among a (C1-C3)alkyl group, a hydroxyl group, a -NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group and a (C1-C4)alkoxy group, and can further be a other groups or anyone of its metabolites or pharmaceutically acceptable salt or anyone of their enantiomers or diastereoisomers, for use for treating or preventing cancer or dysplasia.

  式 (I') 的喹啉衍生物 其中 R 独立地代表一个卤素原子或一个选自(C1-C3)氟烷基、(C1-C3)氟烷氧基、-NR1R2 基团、(C1-C4)烷氧基和(C1-C3)烷基的基团，所述烷基可选择被羟基单取代或二取代，R'独立地代表一个卤素原子或一个选自(C1-C3)烷基的基团、羟基、-NR1R2 基团、吗啉基或吗啉基、N-甲基哌嗪基、(C1-C3)氟烷基和(C1-C4)烷氧基，还可以是其他基团或其代谢物或药学上可接受的盐或其对映体或非对映异构体中的任何一种，用于治疗或预防癌症或发育不良。
• COMPOUNDS USEFUL FOR TREATING AIDS
  申请人：ABIVAX

  公开号：EP2651416B1

  公开（公告）日：2018-05-09